Savara Inc (NASDAQ:SVRA) Shares Acquired by MetLife Investment Management LLC

MetLife Investment Management LLC grew its stake in Savara Inc (NASDAQ:SVRA) by 28.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 66,907 shares of the company’s stock after purchasing an additional 14,883 shares during the period. MetLife Investment Management LLC’s holdings in Savara were worth $284,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. BNP Paribas Financial Markets increased its holdings in shares of Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after purchasing an additional 18,534 shares during the period. FMR LLC grew its holdings in Savara by 9.6% during the third quarter. FMR LLC now owns 1,083,893 shares of the company’s stock worth $4,596,000 after acquiring an additional 95,154 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after acquiring an additional 3,706 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Savara by 238.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock worth $3,865,000 after acquiring an additional 642,259 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Savara during the third quarter worth $174,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

SVRA has been the topic of a number of recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. Finally, HC Wainwright dropped their price objective on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.17.

Insider Activity

In related news, Director Joseph S. Mccracken acquired 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 5.13% of the company’s stock.

Savara Stock Up 3.3 %

SVRA opened at $3.72 on Monday. The business’s fifty day moving average is $3.58 and its two-hundred day moving average is $4.04. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The company has a market cap of $638.43 million, a price-to-earnings ratio of -8.65 and a beta of 0.92. Savara Inc has a one year low of $2.82 and a one year high of $5.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). Analysts anticipate that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.